Cohere Health vs Xsolis (2026)

AI Health Index verifiedAugust 4, 2026
Verdict

The two most substantial utilization management platforms in this index, and they differ on whose side they stand. Cohere sells to health plans, covering utilization management, payment integrity, appeals, care management and policy work with one consistent model of medical necessity, and it holds accreditation that matters because a carrier stays responsible for compliance regardless of which vendor it used. Xsolis is the only vendor here positioned between payer and provider, scoring medical necessity continuously so both parties argue from the same number, with peer reviewed research behind that score and the strongest security posture in the cluster. The shared score is the more interesting idea, because most utilization disputes are arguments about evidence rather than about rules. Neither publishes a bias evaluation, in the one lane where the output can end in care denied.

The case for Cohere Health
  • It is a clinical intelligence platform for the plan rather than a scoring engine, covering utilization management, payment integrity, appeals, care management and policy management under one model of medical necessity.
  • Accreditation is held, which matters because a carrier is not exempt from prior authorization compliance because it used a vendor and the programme must meet a recognised standard.
  • Breadth means one consistent determination logic across functions rather than several systems disagreeing about the same patient.
The case for Xsolis
  • It is the only vendor in this index sitting between payer and provider rather than serving one side, continuously scoring medical necessity so both parties argue from the same number.
  • It is the only vendor in this cluster with peer reviewed research behind its score, published across multiple United States health systems.
  • The security posture is the strongest here, with a risk based certification at the two year tier and a stated human in the loop design.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Cohere Health and Xsolis are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Cohere Health Xsolis
Primary category RCM & Prior Auth AI RCM & Prior Auth AI
Headquarters Boston, Massachusetts Franklin, Tennessee
Website coherehealth.com xsolis.com
Attribute Matrix

Side by Side

Axis
C
Cohere Health
X
Xsolis
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

Cohere Health

The AI Health Index awards Cohere Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Xsolis, Cohere Health grades higher on several axes, including Model Supply Chain Disclosure, FDA and Regulatory Status and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

Xsolis

The AI Health Index awards Xsolis its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Cohere Health, Xsolis grades higher on Model and Technology Transparency and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

FAQ

Questions buyers ask

Should we choose Cohere Health or Xsolis?

On the axes where the AI Health Index separates them, Cohere Health grades higher on several axes, including Model Supply Chain Disclosure, FDA and Regulatory Status and EHR and Interoperability Depth, and Xsolis grades higher on Model and Technology Transparency and AI Liability and Recourse. Cohere Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.

Where do Cohere Health and Xsolis differ most?

The widest separation the AI Health Index records between Cohere Health and Xsolis is on FDA and Regulatory Status, where Cohere Health grades A and Xsolis grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.

Where do Cohere Health and Xsolis grade the same?

The AI Health Index grades Cohere Health and Xsolis the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the RCM & Prior Auth AI page.

Disclosure

Utilization management is the part of this index where an AI output most directly results in care being delayed or denied, and neither vendor publishes a bias evaluation or subgroup performance analysis. The regulatory point is worth restating: a carrier remains responsible for prior authorization compliance regardless of vendor involvement, and at least one state requires the programme to meet a national accreditation standard, so vendor accreditation transfers benefit and its absence transfers burden. Ask both what proportion of AI informed adverse determinations are overturned on appeal, since that number describes calibration better than any accuracy claim.